Phathom Pharmaceuticals (PHAT) Peer Comparison

$5.74

$-0.48 (-7.72%)

As on 30-Oct-2026 16:00EST

Market cap

$467 Mln

Revenue (TTM)

$275 Mln

P/E Ratio

--

P/B Ratio

25.4

Div. Yield

0 %

Edit

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
Market cap ($ Mln)	467	16,932	10,811	5,010	4,522
Revenue ($ Mln)	275	2,497	102	1,156	497
Net Profit ($ Mln)	-83.00	885.14	-349.47	-105.97	128.63
Net Margin (%)	-30.19	35.45	-341.87	-9.17	25.86
RoE (%)	--	46.96	-22.16	--	32.94
Price to Earnings	--	20.78	--	--	42.02
Price-To-Book	25.37	9.23	6.49	1,743.27	9.83

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
Operating Revenue	274.88	2,496.86	102.23	1,155.55	497.40
Cost of Revenue	53.11	93.32	-74.16	87.91	144.39
Gross Profit	152.51	2,236.43	39.20	1,658.90	256.57
Operating Expenses	247.23	1,400.14	583.29	929.29	348.88
Operating Profit (EBIT)	-25.46	1,003.39	-404.89	138.35	4.13
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-83.00	1,065.84	-349.70	-85.09	124.22
Provision for Tax	0.00	180.70	0.00	20.88	-4.41
Profit after Tax (Net Income)	-83.00	885.14	-349.47	-105.97	128.63
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
Shareholder's Funds	-347.64	1,833.83	1,614.53	-191.21	467.46
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	517.76	267.78	63.02	2,622.85	35.03
Current Liabilities	174.90	411.88	89.72	776.08	138.98
Total Liabilities	259.15	2,844.42	1,742.81	2,898.77	413.23

Assets ($ Mln)

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
Non-Current Assets	37.01	1,191.87	768.68	669.93	320.16
Current Assets	308.01	1,321.62	998.59	2,537.78	321.30
Total Assets	259.15	2,844.42	1,742.81	2,898.77	413.23
Total Debt*	2.42	162.20	76.60	636.03	29.00
Net Current Assets	133.11	909.75	908.87	0.00	0.00

Cashflow ($ Mln)

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
Cash From Operating Activities	-166.78	884.27	-232.89	711.20	42.03
Cash Flow from Investing Activities	-0.23	350.44	-521.06	-861.98	2.16
Cash from Financing Activities	-0.29	-969.59	990.71	331.09	-93.39
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
ROCE (%)	159.15	32.82	-24.09	35.24	-5.80
ROE (%)	63.97	46.96	-22.16	-104.75	32.94
ROA (%)	-19.45	28.91	-23.06	-2.29	17.22
EBIT Margin (%)	-8.00	42.02	-341.82	9.82	1.35
Net Margin (%)	-30.19	35.45	-341.87	-9.17	25.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
Revenue Growth (%)	86.75	9.12	133.74	-35.05	38.94
EBIT Growth (%)	89.24	23.13	-18.50	-87.09	121.67
Net Profit Growth (%)	69.77	30.57	-18.42	-114.10	111.69
EPS Growth (%)	72.98	38.78	-2.42	-116.63	133.38
Book Value Growth (%)	28.87	-7.57	48.81	-28.11	46.83

Valuation Ratios

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
Price / Earnings	-5.54	15.79	-21.09	8.98	-45.11
Price / Book Value	25.37	9.23	6.49	1,743.27	9.83
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-25.49	14.90	-29.43	33.08	153.17
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
Debt to Equity	-0.48	0.00	0.00	0.00	0.00
Short term debt to equity ratio	0.00	0.00	0.01	-0.07	0.02
Current Ratio	1.76	3.21	11.13	3.27	2.31
Quick Ratio	1.72	3.14	11.13	3.13	2.25
Interest Coverage	-0.32	--	-1,279.94	0.57	--

Operating Efficiency Ratios

	Phathom Pharmaceuticals (PHAT)	Exelixis (EXEL)	Kymera Therapeutics (KYMR)	PTC Therapeutics (PTCT)	Caredx Inc (CDNA)
Debtors to sales (%)	39.14	13.16	0.00	20.60	9.60
Asset Turnover	0.64	0.82	0.07	0.25	0.67
Receivable days	121.94	43.48	8.82	35.90	51.56
Inventory Days	70.52	96.17	--	261.74	68.47
Payable days	125.18	147.97	--	159.73	26.19
Cash Conversion Cycle	67.28	-8.32	--	137.90	93.85

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly